Summary:
A multi-center, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of RO4995819 versus placebo, as adjunctive therapy in patients with Major Depression Disorder having inadequate response to ongoing antidepressant treatment.
Qualified Participants Must:
• Be between 18 and 65 years of age
•
Have an episode of depression lasting not longer than one year
•
Have at least one but no more than two antidepressant treatment failures within the current depressive episode
•
Have a body mass index between 18 to 35
•
Not have Schizophrenia, Bipolar Disorder, or Substance Abuse within last 6 months
Qualified Participants May Receive:
Compensation for time and travel may be possible.